



Linjing Mu

Kontakt

Linjing Mu

Publikationen (5)

Haider A, Pacher P, Herde A, Spinelli F, Ahmed H, Atz K, Keller C, Weber M, Schibli R, Mu L, Grether U, Knuesel I, Bartelmus C, Gobbi L, Kretz J, Ullmer C, Brink A, Honer M, Woltering T, Muri D, Iding H, Bürkler M, Binder M, Ametamey S. Identification and Preclinical Development of a 2,5,6-Trisubstituted Fluorinated Pyridine Derivative as a Radioligand for the Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors. *J Med Chem* 2020; 63:10287-10306.

Slavik R, Müller Herde A, Haider A, Krämer S, Weber M, Schibli R, Ametamey S, Mu L. Discovery of a fluorinated 4-oxo-quinoline derivative as a potential positron emission tomography radiotracer for imaging cannabinoid receptor type 2. *J Neurochem* 2016; 138:874-86.

Mu L, Slavik R, Müller A, Popaj K, Cermak S, Weber M, Schibli R, Krämer S, Ametamey S. Synthesis and Preliminary Evaluation of a 2-Oxoquinoline Carboxylic Acid Derivative for PET Imaging the Cannabinoid Type 2 Receptor. *Pharmaceuticals (Basel)* 2014; 7:339-52.

Slavik R, Bieri D, Cermak S, Müller A, Krämer S, Weber M, Schibli R, Ametamey S, Mu L. Development and evaluation of novel PET tracers for imaging cannabinoid receptor type 2 in brain. *Chimia (Aarau)* 2014; 68:208-10.

Mu L, Krämer S, Schibli R, Weber M, Cermak S, Müller A, Drandarov K, Slavik R, Bieri D, Ametamey S. Radiolabeling and in vitro /in vivo evaluation of N-(1-adamantyl)-8-methoxy-4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxamide as a PET probe for imaging cannabinoid type 2 receptor. *J Neurochem* 2013; 126:616-24.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch